Innovations in Generative AI and Foundation Models
Boehringer Ingelheim and IBM will be able to employ IBM’s foundation model technology to find new candidate antibodies for the development of effective treatments
IBM has been at the forefront of creating generative AI models that extend AI’s impact beyond the domain of language
Therapeutic antibodies play a key role in the management of numerous illnesses, such as infectious, autoimmune, and cancerous conditions
Researchers from IBM and Boehringer will work together to use in-silico techniques to speed up the antibody discovery process
The defined targets are designed with antibody candidates using IBM’s foundation model technologies, which have proven effective in producing biologics and small molecules with relevant target affinities
IBM is using foundation models and Generative AI to speed up the discovery and development of new biologics and small chemicals, and this study is the latest in this endeavor